18.76

1.05% -0.28

Nurix Therapeutics Inc (NRIX)

Overview News Price History Option Chain Financials Discussions Forecast

Nurix Therapeutics Inc stock is traded at $18.76, with a volume of 402.28K. It is down -1.05% in the last 24 hours and down -0.32% over the past month. Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Previous Close:

$19.04

Open:

$18.95

24h Volume:

402.28K

Relative Volume:

0.47

Market Cap:

$1.44B

Revenue:

$54.55M

Net Income/Loss:

$-193.57M

P/E Ratio:

-6.4913

EPS:

-2.89

Net Cash Flow:

$-181.86M

1W Performance:

-4.41%

1M Performance:

-0.32%

6M Performance:

-5.85%

1Y Performance:

+127.26%

1-Day Range:

$18.72

$19.34

1-Week Range:

$18.29

$19.68

52-Week Range:

$8.11

$29.56

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name

Nurix Therapeutics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

(415) 660-5320

Address

1700 OWENS STREET, SUITE 205, SAN FRANCISCO

Employee

286

Twitter

Next Earnings Date

2024-10-14

Latest SEC Filings

NRIX's Discussions on Twitter

Compare NRIX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRIX Nurix Therapeutics Inc	18.74	1.44B	54.55M	-193.57M	-181.86M	-2.89
VRTX Vertex Pharmaceuticals Inc	474.46	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.63	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	652.19	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	275.24	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.75	28.75B	3.30B	-501.07M	1.03B	-2.1146

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Oct-24-24	Initiated	UBS	Buy
Oct-11-24	Initiated	Jefferies	Buy
Sep-06-24	Resumed	Robert W. Baird	Outperform
Jul-31-24	Initiated	Truist	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-09-23	Initiated	Barclays	Overweight
Feb-28-23	Initiated	Oppenheimer	Outperform
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Dec-29-21	Initiated	H.C. Wainwright	Buy
Oct-14-21	Initiated	SVB Leerink	Outperform
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-30-21	Resumed	Piper Sandler	Overweight
Apr-30-21	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Needham	Buy
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	Stifel	Buy

View All

Nurix Therapeutics Inc Stock (NRIX) Latest News

Feb 06, 2025

Nurix Therapeutics (NASDAQ:NRIX) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat

Feb 06, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Feb 06, 2025

There is no doubt that Nurix Therapeutics Inc (NRIX) ticks all the boxes. - SETE News

Feb 06, 2025

Feb 05, 2025

Trading Day Triumph: Nurix Therapeutics Inc (NRIX) Ends at 18.59, a -1.90 Surge/Plunge - The Dwinnex

Feb 05, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Feb 05, 2025

Morgan Stanley Forecasts Strong Price Appreciation for Nurix Therapeutics (NASDAQ:NRIX) Stock - Defense World

Feb 05, 2025

Feb 04, 2025

NRIX (Nurix Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily

Feb 04, 2025

HC Wainwright Expects Lower Earnings for Nurix Therapeutics - MarketBeat

Feb 04, 2025

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times

Feb 04, 2025

Feb 03, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 2,811 Shares - MarketBeat

Feb 03, 2025

Balanced Outlook on Nurix Therapeutics: Hold Rating Amidst Promising Trials and Uncertainties - TipRanks

Feb 03, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $73,246.50 in Stock - MarketBeat

Feb 03, 2025

Nurix Therapeutics (NRIX) – Research Analysts’ Weekly Ratings Changes - Defense World

Feb 03, 2025

Feb 02, 2025

Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $27.00 at Royal Bank of Canada - MarketBeat

Feb 02, 2025

Nurix Therapeutics (NASDAQ:NRIX) Given New $36.00 Price Target at Stifel Nicolaus - MarketBeat

Feb 02, 2025

Feb 01, 2025

Nurix Therapeutics' SWOT analysis: protein degrader stock's potential - MSN

Feb 01, 2025

Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $36.00 at HC Wainwright - MarketBeat

Feb 01, 2025

Needham & Company LLC Cuts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $28.00 - MarketBeat

Feb 01, 2025

JPMorgan Chase & Co. Issues Pessimistic Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat

Feb 01, 2025

SG Americas Securities LLC Buys 7,141 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World

Feb 01, 2025

SG Americas Securities LLC Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - ETF Daily News

Feb 01, 2025

Q1 EPS Estimate for Nurix Therapeutics Reduced by Analyst - Defense World

Feb 01, 2025

Jan 31, 2025

Nurix Therapeutics (NASDAQ:NRIX) Issues Earnings Results - MarketBeat

Jan 31, 2025

Stifel Nicolaus Raises Nurix Therapeutics (NASDAQ:NRIX) Price Target to $36.00 - Defense World

Jan 31, 2025

Jan 30, 2025